Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Primary rhabdomyosarcoma of the breast in a 17-year-old girl: Case report.

Medicine (Baltimore) 2017 December
RATIONALE: Primary rhabdomyosarcoma of the breast is very rare disease with poor prognosis and no definitive treatment has yet been established.

PATIENT CONCERNS: A 17-year-old girl presented with right breast mass without distant metastasis in image study.

DIAGNOSIS: The result of core needle biopsy was intraductal carcinoma; however, histopathologic finding after mastectomy was primary rhabdomyosarcoma of breast.

INTERVENTIONS: Adjuvant chemotherapy was recommended because resection margin was involved by tumor cells, but she did not visit the clinic anymore. Five months later, tumor recurred with local invasion and chemotherapy of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VAC/IE) was done.

OUTCOMES: In the course of chemotherapy and sequential follow-up, there was no tumor growth until now.

LESSONS: Primary breast rhabdomyosarcoma is an uncommon disease, as a result diagnosis is often delayed. For the same reason, there is little information about treatment. This report may be helpful for managing the disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app